Clinical study on the activation and release of interleukin-18 by AIM2 inflammasome in peripheral blood mononuclear cells to mediate herpes zoster
Objective:To explore the release of interleukin-18(IL-18)from AIM2 inflammasome activation in peripheral blood mononuclear cells(PBMC)of herpes zoster patients at different stages and to conduct preliminary validation.Methods:From April 2022 to January 2024,at Huazhong University of Science and Technology Union Shenzhen hospital,peripheral blood mononuclear cells and serum were collected and isolated from 67 patients with acute herpetic neuralgia(AHN),58 patients with subacute herpetic neuralgia(SHN),38 patients with post-herpetic neuralgia(PHN),and 30 healthy controls.The genes and proteins related to absence in melanoma 2(AIM2)inflammasome were detected using Real-time quantitative PCR,western blotting,and protein chip technology.Results:Compared with healthy individuals,in gene expression and protein level,the expressions of AIM2 and IL-18 increased significantly in different stages of herpes zoster(P<0.05),particularly in the PHN stage(P<0.001).Cleavage of GSDMD produces GSDMD-NT fragments that have the ability to form pores in the cell membrane,ultimately leading to pyroptosis.The level of IL-18 secretion in the serum of patients with herpes zoster increases significantly in different stages,particularly during the PHN stage.Conclusion:The activation of the AIM2 inflammasome in peripheral blood mononuclear cells and the subsequent release of IL-18 are implicated in the onset and progression of herpes zoster disease.
万方数据
维普
